MinervaX is pursuing the development of a maternal vaccine for the prevention of adverse pregnancy outcomes and life-threating infections caused by Group B streptococcus (GBS). The vaccine is based on adjuvanted proteins antigens covering close to 100% of clinical GBS isolates.
Group B Streptococcal (GBS) is the leading cause of life-threatening infections in newborns. Colonization of pregnant women with GBS may lead to adverse pregnancy outcomes such as late abortions, stillbirths, and preterm delivery. Colonization may also lead to life-threatening infections in newborns for the first 3 months of life, causing pneumonia, septicemia and meningitis, which may lead to death or life-long disability.
Annually, GBS is responsible for some 320,000 cases of neonatal invasive disease, 60,000 stillbirths, 3,500,000 preterm deliveries, and 10,000 babies suffering from long-term neurological damage world-wide.
Group B Streptococcal (GBS) is the leading cause of life-threatening infections in newborns. Colonization of pregnant women with GBS may lead to adverse pregnancy outcomes such as late abortions, stillbirths, and preterm delivery. Colonization may also lead to life-threatening infections in newborns for the first 3 months of life, causing pneumonia, septicemia and meningitis, which may lead to death or life-long disability.
Annually, GBS is responsible for some 320,000 cases of neonatal invasive disease, 60,000 stillbirths, 3,500,000 preterm deliveries, and 10,000 babies suffering from long-term neurological damage world-wide.
Location: Denmark, Capital Region of Denmark, Copenhagen
Employees: 1-10
Total raised: $196.51M
Investors 4
| Date | Name | Website |
| 30.01.2021 | Industrifo... | industrifo... |
| - | Adjuvant C... | adjuvantca... |
| 18.11.2023 | OrbiMed | orbimed.co... |
| 22.12.2020 | Wellington... | wellington... |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 12.10.2023 | - | $57.26M | - |
| 15.12.2022 | - | $76.43M | Trill Impa... |
| 15.12.2020 | Series B | $57.81M | Industrifo... |
| 22.01.2019 | - | $5M | - |
Mentions in press and media 13
| Date | Title | Description |
| 20.06.2024 | Denmark: Europe's hub for tech innovation and collaboration | Denmark's tech ecosystem thrives on innovation, collaboration, and sustainability. Centered in Copenhagen, it supports a diverse range of sectors including biotechnology, renewable energy, and digital innovation. The city's vibrant startup ... |
| 12.10.2023 | Denmark-based MinervaX announces closure of Upsized financing at USD 54 million | Copenhagen, Denmark-based biotechnology company developing a novel, prophylactic vaccine against Group B Streptococcus (GBS), MinveraX, closed upsized financing at USD 54 million. The round took place on October 11, 2023. New investors such... |
| 11.10.2023 | MinervaX Raises EUR 54M in Upsized Financing to Advance the Development of its Maternal Vaccine Against Group B Streptococcus | - |
| 11.10.2023 | MinervaX Raises EUR 54M in Upsized Financing | MinervaX, a Copenhagen, Denmark-based biotechnology company, raised EUR54M in upsized financing. The round was led by EQT Life Sciences and OrbiMed, with participation from existing investors Novo Holdings, Pureos Ventures, Sanofi Ventures,... |
| 11.10.2023 | Denmark’s MinervaX raises €54M to prevent life-threatening infections caused by Group B streptococcus | Read this article in: Denmark-based biotechnology company MinervaX ApS announced the completion of a €54M upsized financing. MinervaX aims to use the funding to boost the development of a novel prophylactic vaccine against Group B Streptoco... |
| 15.12.2022 | MinervaX Raises €72M Financing | MinervaX, a Copenhagen, a Denmark-based biotechnology company, raised €72M in funding. The €22M equity round was led by Trill Impact Ventures and Pureos Bioventures with participation from REPAIR Impact Fund, Sunstone Life Science Ventures,... |
| 15.12.2022 | Trill Impact Ventures co-leads the EUR 22M financing round in MinervaX | Trill Impact Ventures co-leads the EUR 22M financing round in MinervaX Thu, Dec 15, 2022 08:00 CET Report this content Advancing novel maternal vaccine against Group B Streptococcus (GBS) December 15th, 2022 Trill Impact Ventures, Trill Imp... |
| 16.12.2020 | MinervaX Raises Upsized Eur 47.4 Million (USD 57M) Series B to Advance Its Novel Group B Streptococcus Vaccine | On the back of highly promising Phase Ib data, MinervaX has raised financing from leading investors to accelerate development of its novel vaccine through the end of Phase II trials and preparations for Phase III pivotal trials MinervaX, a ... |
| 15.12.2020 | MinervaX raises $57M for Group B streptococcus vaccine race with Pfizer | Despite decades of research, there is still no effective vaccine against Group B streptococcus (GBS), a leading cause of infant mortality worldwide. But MinervaX thinks it’s on course to change that, and now it has the cash it needs to push... |
| 15.12.2020 | MinervaX raises $57M for Group B streptococcus vaccine race with Pfizer | Despite decades of research, there is still no effective vaccine against Group B streptococcus (GBS), a leading cause of infant mortality worldwide. But MinervaX thinks it’s on course to change that, and now it has the cash it needs to push... |
Show more